This study looks at using two drugs, DFMO (Difluoromethylornithine) and Etoposide, to help treat a type of cancer called neuroblastoma. Neuroblastoma is a cancer that starts in certain nerve cells. The study is for patients whose cancer has come back or hasn't responded to previous treatments.
Participants will take the drugs in cycles: six 21-day cycles of both drugs, followed by 630 days of DFMO alone. There are three groups in this study:
- Those with no active disease after other treatments.
- Those who had a relapse but currently have no active disease.
- Those with active disease.
Key Points:
- The study lasts for about 2 years.
- Participants must have completed previous cancer treatments.
- Regular monitoring of health and recovery is required.
To join the study, participants must meet certain health conditions and agree to use birth control if of childbearing age. If you have an infection or are using other experimental drugs, you cannot join. Participants must also give their informed consent to participate.
How understandable was the trial content above?
Hard to understand
Easy to understand